PRRT2 and Alzheimer disease: Previous works have revealed that many kinase levels are modified in the brain and CSF of AD patients including glycogen synthase kinase 3 (GSK3; Pei et al., 1997), cyclin dependent kinase 5 (CDK 5; Baumann et al., 1993), c-Jun N-terminal kinase (JNK; Gourmaud et al., 2015), mamalian target of rapamycin (mTOR; Lafay-Chebassier et al., 2005), proapoptotic kinase R (PKR) (Chang et al., 2002b), protein kinase C (PKC; Masliah et al., 1990).